|
BIOTECH STOCKS CV Therapeutics falls; biotechs mixed By Ted Griffith, CBS.MarketWatch.com Last Update: 9:45 AM ET Dec. 8, 2003 BOSTON (CBS.MW) -- Biotechnology stocks were mixed in early trading Monday, with shares of CV Therapeutics tumbling ahead of a crucial regulatory review. The Amex Biotechnology Index (BTK: news, chart, profile) dipped 0.3 percent, while the Nasdaq Biotechnology Index (NBI: news, chart, profile) edged up 0.3 percent. CV Therapeutics (CVTX: news, chart, profile) plunged $2.80, or 16.7 percent, to $13.96. A Food and Drug Administration advisory panel on Tuesday is expected to make a recommendation on whether CV Therapeutics` experimental angina treatment, Ranexa, should be approved. The FDA typically follows the recommendations of its advisory panels. Among the leading gainers, shares of American Pharmaceutical Partners (APPX: news, chart, profile) jumped $1.65 to $37.15. The drugmaker late Friday said its breast cancer therapy produced encouraging results in late-stage patient testing. Ted Griffith is a reporter for CBS.MarketWatch.com |
|
| aus der Diskussion: | +++ CV Therapeutics Inc (CVTX) - Kurssturz +++ |
| Autor (Datum des Eintrages): | kosto1929 (08.12.03 16:36:26) |
| Beitrag: | 4 von 470 (ID:11549326) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |